Daiichi Sankyo And Aussie Biotech Biota Begin Phase III Asian Trials For Second-Generation Flu Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Long-acting second-generation LANIs have a compliance advantage in once-only for treatment and once-weekly for prophylaxis dosing.
You may also be interested in...
Aussie Biotech Biota Completes Phase II Trials for Relenza Follow-On; Phase III To Be Conducted In Japan, Taiwan, Hong Kong and Korea
PERTH, Australia - Australian biotech Biota completed Phase II trials for its second-generation influenza compound CS-8958; the trials successfully met all endpoints, the company announced July 31
Asia Spotlight: Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.
Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China: An Interview With PharmAsia News (Part 2 of 2)
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.